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Objective: Recent studies suggest that urodilatin from the kidneys rather 
than atrial natriuretic factor from the heart is the more important member 
of the family of natriuretic peptides involved in the normal regulation of 
renal sodium and water excretion. We thus examined the relationship 
between natriuresis, urodilatin, and atrial natriuretic factor in patients 
after cardiopulmonary bypass, a procedure known to increase levels of 
atrial natriuretic factor significantly. Methods: Excretion rates of sodium 
and water were correlated with the excretion of urodilatin and with 
circulating levels of atrial natriuretic factor, antidiuretic hormone, aldo- 
sterone, and plasma renin activity during a period of 16 hours in 12 
patients having had coronary artery bypass operations and with approxi- 
mately a 400% elevation in levels of atrial natriuretic factor. Results: 
Natriuresis did not correlate with atrial natriuretic factor, antidiuretic 
hormone, aldosterone, or plasma renin activity. Excretion rates of urodi- 
latin, however, correlated significantly with excretion rates of sodium (r = 
0.74, p = 0.03), urine flow (1" = 0.83, p = 0.01), and with levels of serum 
sodium (r = 0.82,p = 0.01). Conclusion: These results suggest an important 
role for urodilatin, greater than that of atrial natriuretic factor, in the 
regulation of renal excretion of sodium and water after cardiopulmonary 
bypass surgery. (J Thorac Cardiovasc Surg 1997;114:666-71) 
T he most recently isolated member of the family of natriuretic-vasorelaxant peptides (ANF-[95-126] 
or CDD[ANP-95-126]), named urodilatin, 1is prob- 
ably produced within the nephron by different post- 
translational processing of the prohormone atrial 
natriuretic factor (ANF)-(1-126)) 
By intravenous infusion, urodilatin has greater 
natriuretic effects than ANF-(99-126) (ANF) in 
normal human beings, 3 in experimental nimals, 4' 5 
and in experimental models of congestive heart 
failure.6, 7 This difference in natriuretic potency has 
been explained by differences in clearance mecha- 
nisms: whereas urodilatin is removed from the cir- 
culation mainly by clearance receptors, ANF is 
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cleared by both clearance ANF receptors and the 
enzyme neutral endopeptidase. 8' 9 Although of con- 
siderable therapeutic interest, the value of these 
studies for understanding the physiologic impor- 
tance of urodilatins may well be more ditficult to 
extract, because the peptide is only found in urine. 1° 
Primarily based on correlation studies, recent 
reviews further suggest that in human beings, urodi- 
latin, rather than ANF from the heart, might be the 
more important member of the ANF family in- 
volved in the regulation of renal sodium excre- 
tion. 11-13 
So far, however, studies in human beings have 
included only healthy subjects with normal evels of 
circulating ANF. It is thus uncertain whether a 
better correlation exists between renal function and 
urodilatin excretion than between renal function 
and levels of ANF when ANF values are very high. 
Because previous tudies have suggested that ANF 
is involved in the not yet fully understood effects of 
cardiopulmonary bypass (CPB) on renal func- 
tion,14, is and because ANF increases significantly in 
response to this procedure, 14' 15 we examined the 
relationship between renal function (natriuresis, 
urine flow), nrodilatin, ANF, antidiuretic hormone 
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(ADH), aldosterone, plasma renin activity (PRA), 
cortisol, serum sodium, plasma cyclic guanosine 
monophosphate, and hemodynamics in patients 
having had CPB operations approximately 24 hours 
earlier. 
Methods 
Subjects. Twelve patients having had coronary bypass 
graft operations (five women and seven men, aged 42 to 
73 years) were studied. All patients gave their informed 
consent according to the Declaration of Helsinki, and the 
study was approved by the ethical committee of the 
hospitals. Circulating hormone levels in patients were 
compared with those of 10 healthy control subjects (five 
women and five men, aged 27 to 73 years). Because of the 
risk of infection associated with bladder catheterization in 
healthy subjects, no urine parameters were obtained from 
the control subjects. The patients were supported by CPB 
for an average of 59.1 +_ 5.3 minutes (range 34 to 91 
minutes). They- were all cooled, and the aorta was cross- 
clamped for 28 _+ 2,3 minutes (range 18 to 47 minutes). 
The study began 30.4 -+ 0.6 hours after CPB was stopped 
(range 26 to 32 hours). None of the patients had reopera- 
tions. 
Study design. Experimental investigations suggest that 
cardiac baroreceptors are involved in the regulation of 
urodilatin release, a6 Because most anesthetics influence 
the function of such receptors, 17we studied the patients 
during the twenty-fourth to forty-eighth postoperative 
hours to assure that little or no anesthetic remained in the 
patients. This protocol further reduced the influence of 
drugs with cardiovascular (and thus renal) action, fre- 
quently administered in the early postoperative period. 
Thus, apart from an intravenous dosage of furosemide to 
eight patients to maintain a high urinary output, no drugs 
were given during the study. 
All patients had a urinary catheter and a central venous 
catheter through which central venous pressure (CVP) 
was measured and blood samples were drawn. The pa- 
tients remained in the supine position during the entire 
study period. The patients were transferred to the ward 
from the intensive care unit around 11 AM. The study 
began at 6 PM, after the patients had had supper, and was 
terminated 16 hours later at 10 AM, when catheters were 
removed. For the duration of the study, urine flow and 
urina_ry electrolyte xcretion were monitored at 2-hour 
intervals, and the urine was sampled for urodilatin deter- 
mination. Every 2 hours blood was drawn for hormone 
determinations, and blood pressure (sphygmomanome- 
try), heart rate, and CVP were measured. No dietary 
restrictions were made. The control subjects were studied 
in the afternoon. Blood was sampled through an antecu- 
bital venous catheter after 2 to 3 hours of supine rest. All 
blood and Urine was sampled in prechilled tubes, imme- 
diately spun for 10 minutes at 3000 rpm and 4 ° C, and the 
supernatants were frozen at -80 ° C. 
Determinations. Circulating hormones were deter- 
mined by commercial radioimmunoassays as previously 
described18: ANF (Peninsula, Belmont, Calif.) after C-18 
extraction, aldosterone (Sorin, Saluggia, Italy), PRA 
(NEN, Billerica, Mass.), and cortisol (Biermann, Bad 
Nauheim, Germany). Sensitivity, intraassay, and interas- 
say variability for ADH and melatonin (Nichols, Wijchen, 
The Netherlands) were 1.3 pg/ml, 6.7%, and 6.9% and 3 
pg/ml, 5.9%, and 8%, respectively. With the exception of 
ADH, which was determined in heparinized plasma, all 
hormones were measured in plasma treated with ethyl- 
enediaminetetraacetic acid (with aprotinin [Bayer, Le- 
verkusen, Germany], added for ANF). Urodilatin was 
determined from ethanol-extracted urine treated with 
ethylenediaminetetraacetic acid by a specific antibody not 
cross-reacting with ANF, as recently described. 19Sensitiv- 
ity was 7 pmol/L, and intraassay and interassay variabili- 
ties were 8% and 12%, respectively. Concentrations of
sodium in urine and in serum were measured with the use 
of ion-selective lectrodes (Na-K Analyzer 614, CIBA- 
Corning, Fernwald, Germany, and Hitachi 717 AutoAna- 
lyzer, Boehringer , Mannheim, Germany, respectively). 
The assay for measuring cyclic guanosine monophosphate 
has previously been described in detail. 2° 
Statistics. Friedman's test and Wilcoxon's test with the 
method of Bonferroni were used for testing for circadian 
variability. Wilcoxon's test was used for comparisons 
within a group, the Mann-Whitney test to compare pa- 
tients with control subjects, and Pearson's least square 
method for the correlation analyses, using the statistical 
program of NCSS (Hintze, Kaysville, Utah). The level of 
statistical significance was set atp < 0.05. The designation 
p = NS indicates "not significant." Values are presented 
as means _+ standard error. Urine variables are given as 
excretion rates in units per minute. 
Results 
Figs. 1 and 2 show the excretion rates of urodila- 
tin, urine, and sodium, serum levels of sodium, and 
the hormone levels in plasma during the eight study 
periods. Neither ANF (Fig. 3), aldosterone, ADH, 
PRA, nor cortisol showed any significant correlation 
with either urine flow or sodium excretion (all p = 
NS). The excretion rates of urodilatin, however, 
correlated significantly with excretion rates of so- 
dium (r = 0.74, p = 0.03), with urine flow (r = 0.83, 
p = 0.01) (Fig. 3), and with levels of serum sodium 
(r = 0.82, p = 0.01). CVP further correlated with 
sodium excretion (r = 0.87, p = 0.005). The signif- 
icant correlations persisted after bmission of the 
furosemide-stimulated values: urodilatin versus So- 
dium excretion: r = 0.78,p = 0.02; urodilatin versus 
urine flow: r = 0.77,p = 0.03. Plasma levels of cyclic 
guanosine monophosphate correlated neither with 
levels of ANF nor with excretion rates of urodilatin 
(bothp = NS). 
The hemodynamic parameters (blood pressure, 
heart rate, and CVP) were remarkably stable during 
the study (Fig. 2), showing no indication of circadian 
variability (all p = NS). Whereas mean levels of 
ANF of the individual patients did not correlate with 
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Fig. 1. Renal excretion rates of urodilatin, urine, and sodium, and serum/plasma levels of sodium, ANF, 
aldosterone, ADH, and PRA during the eight 2-hour periods in 12 patients tudied 30.4 _+ 0.6 to 46.4 _+ 
0.6 hours after CPB was stopped. Means _+ standard errors. 
mean values of CVP or blood pressure (p = NS), the 
mean excretion rates of urodilatin showed a significant 
correlation with CVP (r = 0.62, p = 0.03) and with 
diastolic blood pressure (r = 0.76, p = 0.005). 
With the exception of aldosterone, plasma hor- 
mone levels were significantly higher than in the 
control subjects: ANF ]79 _+ 21 versus 45 _+ 5 pg/ml 
(p = 0.0001), ADH 13.4 _+ 2.3 versus 2.6 _+ 0.4 pg/ml 
(p = 0.0001), PRA 6.8 _+ 2.9 versus 1.0 _+ 0.2 ng/ml per 
hour (p = 0.0006), and aldosterone 0.31 _+ 0.07 versus 
0.20 _+ 0.04 nmol/L (p = NS). 
Compared with preoperative values, serum creat- 
inine levels during the study were unchanged (1.1 +_ 
0.05 vs 1.18 _+ 0.08 mg/dl, p = NS); serum levels of 
urea were slightly elevated (34.5 + 2.1 vs 47.6 _+ 3.3 
mg/dl). No patients had renal insufficiency. During 
the study, patients lost 627 + 109 gm in weight. This 
weight loss did not correlate with urodilatin excre- 
tions or with ANF levels (both p = NS). 
The intravenous administration of furosemide 
caused a short-lived increase in urine flow in alt 
(1.04 _+ 0.13 to 2.14 _+ 0.46 ml/min, p = 0.01); the 
excretion rate of urodilatin dropped in all but two 
patients (89 _+ 29 vs 65.3 _+ 19.1 fmol/min). This 
decrease, however, did not reach statistical signifi- 
cance (p = NS). 
Plasma cortisol levels did not show the typical 
steep rise from a midnight nadir, but remained 
elevated at values around 600 nmol/L. Therefore, to 
check for a general paralysis of circadian oscillators 
in this group of patients who had been newly 
operated on, we measured levels of melatonin in 
properly handled remnant plasma samples. Fig. 2 
shows a normal profile for plasma melatonin with a 
significant peaking around 4 AM (p = 0.008). 
Discussion 
Our data show that even during the postoperative 
period of sustained, significantly elevated levels of 
ANF (ADH and PRA), urodilatin excretion corre- 
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Fig. 2. Systolic and diastolic blood pressures, heart rate, 
CVP, plasma levels of melatonin, and cortisol (top to 
bottom) during the eight 2-hour periods in 12 patients 
studied 30.4 -+ 0.6 to 46.4 _+ 0.6 hours after CPB was 
stopped. Means +_ standard errors. 
lates better with excretion rates of sodium and urine 
than do plasma levels of ANF, ADH, aldosterone, and 
PRA. These results agree with those of Drummer and 
associates, 21 who showed that the excretion of urodi- 
latin closely paralleled circadian urinary excretion of 
sodium and urine in six normal men, as well as during 
acute volume loading with saline solution. 
Inasmuch as a statistical correlation is not evi- 
dence of cause or effect, the significant positive 
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Fig. 3. Correlations between sodium and urodilatin ex- 
cretions, sodium excretion and plasma levels of ANF, 
urine flow and urodilatin excretions, and urine flow and 
plasma levels of ANF (top to bottom). 
and urine raises the question of a "washout" phe- 
nomenon. This, however, seems not to be the case, 
because furosemide increased urine flow in all eight 
patients but induced a drop, although statistically 
insignificant, in urodilatin excretion. It is thus un- 
likely that a significant correlation is due to urodi- 
latin passively following urine flow. 
Although the factors that regulate synthesis and 
release of urodilatin remain obscure, u studies by 
Goetz and coworkers 16 have suggested that cardiac 
nerves modulate the excretion of urodilatin. Left 
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atrial distention increased urinary sodium and 
urodilatin excretion and plasma ANF in cardiac 
innervated dogs, whereas atrial distention, after 
cardiac denervation, caused an increase in ANF 
alone. The rise in diuresis and urodilatin excretion 
after an infusion of saline solution, however, did not 
appear to depend on intact cardiac innervation. 16 
The significantly better correlation in the present 
study between individual mean levels of urodilatin 
excretion and mean values of CVP (and diastolic 
blood pressure), than between these two parameters 
and plasma ANF, are in line with the results of the 
aforementioned experiments and with the results 
from human subjects exposed to an increase in 
central blood volume through water immersion. =
Recently, Emmeluth and colleagues 23demonstrated 
a significant increase in renal sodium and urodilatin 
excretion after a selective 2% increase in sodium 
concentration i the carotid arteries in conscious 
dogs. A comparable isotonic volume expansion 
caused a significantly smaller increase in sodium 
excretion and no changes in urodilatin excretionY 
These findings are supported by the significant 
correlation between comparable variations in serum 
sodium (about 1.5%) and urodilatin excretion in the 
present study. Thus, taken together, these results 
suggest hat the release of urodilatin in human 
beings might be modified by hemodynamics, includ- 
ing stimulation of intracardiac receptors, and by 
levels of serum sodium. 
The mean excretion rate of urodilatin in our 
patients (98 fmol/min) was threefold to sixfold 
higher than the values reported from healthy sub- 
jects (15 to 35 fmol/min) 1°' 22 in studies that used a 
measuring procedure, type of synthetic urodilatin, 
and antibodies identical to those of the present 
study. This might suggest that urodilatin release was 
stimulated postoperatively in our patients, none of 
whom had renal insufficiency. Renal failure, how- 
ever, is a frequent complication after cardiac trans- 
plantation, a procedure which, theoretically, could 
interfere with urodilatin release in at least two ways: 
through the nephrotoxicity of cyclosporine (INN: 
ciclosporin) and as a result of the severing of major 
parts of cardiac nervous connections. It is therefore 
interesting that the administration of urodilatin in 
the early postoperative phases after heart transplan- 
tation appears to improve renal function 24 or, at 
least, reduce the duration of hemofiltration and 
frequency of hemodialysis compared with placebo. 25 
However, at present we do not know whether urodi- 
latin excretion after cardiac transplantation is com- 
promised or whether patients in whom renal insuf- 
ficiency develops after CPB have a suppressed 
urodilatin release. 
In conclusion, results of the present study add 
further support o the concept of an important role 
for urodilatin (and a superior ole to that of ANF) in 
the renal regulation of sodium and water excretion, 
also in patients with very high levels of circulating 
ANF who have had operations involving CPB. 
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